Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
CRESEMBA (Isavuconazonium) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 6 months; Continuation- 6 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage **CRESEMBA (Isavuconazonium).** Please complete all sections, incomplete forms will delay processing. Fax this form back to Kaiser Permanente within 24 hours fax: 1-866-331-2104. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless all sections are complete. KP-MAS Formulary can be found at:** **http://www.providers.kaiserpermanente.org/mas/formulary.html**

1 – Patient Information

Patient Name: ______________________________ Kaiser Medical ID#: _________________ Date of Birth: _____________

2 – Prescriber Information

Is the prescriber an infectious disease specialist, hematologist/oncologist, or transplant specialist? □ No □ Yes

If consulted with a specialist, specialist name and specialty: ____

Prescriber Name: ______________________________ Specialty: ____________________________ NPI: _________________

Prescriber Address: ____

Prescriber Phone #: __________________________Prescriber Fax #: ___________________________

3 – Pharmacy Information

Pharmacy Name: ________________________________ Pharmacy NPI: ____

Pharmacy Phone #_______________________________ Pharmacy Fax #: ____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: ____
Sig: ____

Drug 2: Name/Strength/Formulation: ____
Sig: ____

5– Diagnosis/Clinical Criteria

1. Is this request for initial or continuing therapy?
   □ Initial therapy □ Continuing therapy, State date: _______________________
2. Indicate the Member's diagnosis for the requested medication: ____
3. Member is 18 years of age or older?
   □ No □ Yes

-AND-

4. Does the member have a diagnosis of invasive aspergillosis? **AND**
   □ No □ Yes
5. Has treatment failure/intolerance of voriconazole? **OR**
   □ No □ Yes
6. Did Voriconazole have a drug-drug interaction with the individual's current therapy which requires therapy modification?
   □ No □ Yes

-OR-

7. Does the member have diagnosis of invasive mucormycosis? **AND**
   □ No □ Yes
8. Has treatment failure/intolerance of Posaconazole? **OR**
   □ No □ Yes
9. Did Posaconazole have a drug-drug interaction with the individual's current therapy which requires therapy modification?
   □ No □ Yes

-OR-

10. Is there documentation supporting use of the requested agent for primary or secondary prophylaxis of invasive fungal infections in patients who have documented intolerance and/or drug-drug interactions which require therapy modification to posaconazole and voriconazole?
    □ No □ Yes

For Continuation of Therapy, Please Respond to Additional Questions Below:

1. Does the member continue to be followed by an infectious disease specialist, hematologist/oncologist, or transplant specialist; follow-up has occurred in the past 6 months?
   □ No □ Yes
2. Has the member demonstrated positive clinical and/or laboratory response to therapy?
   □ No □ Yes

6 – Prescriber Sign-Off

Additional Information – Please submit chart notes/medical records for the patient that are applicable to this request. Provide any additional supporting information that should be taken into consideration:

____

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Prescriber Signature:	Date:

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility